-
Hansoh Pharmaceutical Gets NMPA Approval for HS-10518 Clinical Study in Endometriosis Pain
•
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its Category 1 drug HS-10518 (TU2670). The study will focus on the treatment of moderate to severe pain associated with endometriosis and menorrhagia associated with…
-
MicroPort MedBot’s Dragonfly Eye 3D Endoscopy Earns CE Mark for Intraperitoneal Procedures
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its in-house developed Dragonfly Eye 3D electronic intraperitoneal endoscopy has received the CE mark, a significant milestone for the company’s innovative medical device. High-Definition Imaging and Surgical PrecisionThe Dragonfly Eye 3D is a state-of-the-art three-dimensional electronic abdominal endoscope designed…
-
Merck KGaA Expands High-Purity Reagents Production in Nantong, China with EUR 70 Million Investment
•
Germany-based Merck KGaA (NYSE: MRK) has announced plans to expand production capacity for highly-purified reagents at its Nantong site in China, a strategic location within the Yangtze River Delta region known for its major transportation hub. The investment, valued at approximately EUR 70 million (USD 76 million), will enable large-scale…
-
Shanghai Pharmaceuticals’ MediTrust Health Partners with Yuanda Shuyang on Rare Disease Treatment Model
•
Shanghai Pharmaceuticals Holding Co., Ltd’s (SHA: 601607, HKG: 2607) subsidiary, MediTrust Health, which specializes in insurance, financing, and direct-to-patient pharmacy services, has entered into a partnership with Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. The collaboration aims to strengthen the development of a “Chinese model” for the diagnosis and treatment of…
-
Qilu Pharmaceutical’s Iruplinalkib Receives NMPA Approval for ALK+ NSCLC Treatment
•
China-based Qilu Pharmaceutical has announced that its Category 1 chemical drug, iruplinalkib, an ALK inhibitor, has obtained marketing approval from the National Medical Products Administration (NMPA). This approval allows the use of iruplinalkib to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that harbor anaplastic lymphoma…
-
Jiangsu Hengrui’s Oteseconazole (SHR8008) Approved by NMPA for Severe Vulvovaginal Candidiasis
•
The National Medical Products Administration (NMPA) has granted approval to China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) for its drug oteseconazole (SHR8008), which will be used to treat severe vulvovaginal candidiasis (VVC). This marks a significant advancement in the treatment options for patients suffering from VVC. Oteseconazole: A Selective…
-
Pfizer Partners with CSPC Pharmaceutical to Localize Paxlovid in China
•
US pharmaceutical major Pfizer (NYSE: PFE) has entered into a partnership with China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) to localize its antiviral treatment Paxlovid (nirmatrelvir + ritonavir) in China. This collaboration aims to enhance access to the COVID-19 therapy within the Chinese market. Paxlovid: An Oral Small Molecule COVID-19…
